Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer

Soluble CD44 is present in the serum of normal individuals (2.7 +/- 1.1 nM). The concentration of soluble CD44 in the serum is elevated in patients with advanced gastric (24.2 +/- 9.8 nM) or colon cancer (30.8 +/- 11 nM). Serum CD44 concentration correlated with tumor metastasis and tumor burden. Su...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1994-01, Vol.54 (2), p.422-426
Main Authors: Guo, Y J, Liu, G, Wang, X, Jin, D, Wu, M, Ma, J, Sy, M S
Format: Article
Language:English
Subjects:
Adenocarcinoma - blood
Adenocarcinoma - pathology
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers, Tumor - blood
Colonic Neoplasms - blood
Colonic Neoplasms - pathology
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Hyaluronan Receptors
Male
Medical sciences
Middle Aged
Molecular Weight
Neoplasm Staging
Receptors, Lymphocyte Homing - analysis
Stomach Neoplasms - blood
Stomach Neoplasms - pathology
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soluble CD44 is present in the serum of normal individuals (2.7 +/- 1.1 nM). The concentration of soluble CD44 in the serum is elevated in patients with advanced gastric (24.2 +/- 9.8 nM) or colon cancer (30.8 +/- 11 nM). Serum CD44 concentration correlated with tumor metastasis and tumor burden. Surgical resection of tumors resulted in decreases in serum CD44 levels. By Western blot analysis, monoclonal anti-CD44 antibody reacted with a major protein with molecular weight between 130,000 and 190,000. In addition, two proteins with molecular weights of 72,000 and 80,000 can also be identified. Therefore, different CD44 isoforms may be present in the serum of cancer patients. Serum CD44 concentrations may be an indicator of tumor burden and metastasis in patients with malignant diseases.
ISSN:0008-5472
1538-7445